Aurinia Pharmaceuticals (AUPH) vs Lakefront Biotherapeutics (LKFT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lakefront Biotherapeutics (LKFT) has outperformed Aurinia Pharmaceuticals (AUPH) over the past year, gaining 8.6% versus a loss of 6.3%. Over five years, AUPH leads with a -24.0% price change compared with -31.8% for LKFT. Lakefront Biotherapeutics is the larger company by market cap ($2.18 billion vs $1.97 billion), about 1.1 times the size.
On valuation, Lakefront Biotherapeutics trades at a lower trailing P/E (2.4x vs 6.4x for Aurinia Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | LKFT |
|---|---|---|
| Share price | $14.70 | $33.31 |
| Market cap | $1.97B | $2.18B |
| 1-day change | -1.28% | -0.24% |
| YTD return | -7.84% | +1.87% |
| 1-year return | -6.25% | +8.64% |
| 5-year return | -23.95% | -31.80% |
| P/E ratio (TTM) | 6.45 | 2.39 |
| Forward P/E | 12.67 | — |
| EPS (TTM) | $2.28 | $13.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $283.06M | — |
| Revenue growth (YoY) | +20.38% | — |
| Net income (latest FY) | $287.20M | — |
| Gross margin | 88.46% | — |
| Operating margin | 37.06% | — |
| Net margin | 101.47% | — |
| 52-week high | $19.25 | $36.24 |
| 52-week low | $13.52 | $25.68 |
| Distance from 52-week high | -23.64% | -8.08% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +25.85% | -7.39% |
| Average volume | 858.74K | 280.49K |
| Shares outstanding | 134.00M | 65.48M |
| Employees | 128 | 196 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LKFT has outperformed AUPH by 14.9 percentage points over the past year.
- Aurinia Pharmaceuticals trades at a higher earnings multiple (6.4x vs 2.4x trailing P/E).
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Lakefront Biotherapeutics
LKFT stock →Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees
AUPH vs LKFT FAQ
Which is bigger, Aurinia Pharmaceuticals or Lakefront Biotherapeutics?
Lakefront Biotherapeutics (LKFT) is larger, with a market capitalization of $2.18B compared with $1.97B for Aurinia Pharmaceuticals (AUPH).
Which stock has performed better over the past year, AUPH or LKFT?
LKFT returned +8.64% over the past 12 months, compared with -6.25% for AUPH (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AUPH or LKFT?
LKFT has the lower trailing P/E at 2.4, versus 6.4 for AUPH. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Aurinia Pharmaceuticals and Lakefront Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.